Hormone contraception in women;Contraception hormonale chez la femme

Medecine Therapeutique

Volumn 2, Issue 6, 1996, Pages 453-470

  Duranteau, Lise ^a   Logerot Lebrun, Hélène ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLEANE; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTODENE; LEVONORGESTREL; LYNESTRENOL; NANDROLONE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; TESTOSTERONE; UNCLASSIFIED DRUG;

DRUG EFFECT; DRUG SAFETY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; REVIEW; RISK FACTOR; VEIN THROMBOSIS;

EID: 0029841816     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Toulemon L, Leridon H. 1991. Vingt années de contraception en France . 1968-1988. Population 46 : 777-812.
2. De Lignières B., Vincens M., Basdevant A. 1986. Œstrogènes naturels et artificiels. Aspects thérapeutiques. In : Mauvais Jarvis P., Sitruk Ware R., éds. Médecine de la reproduction. Gynécologie endocrinienne. Parts : Flammarion Médecine-Sciences, 538-552.
3. Sitruk-Ware R. 1986. Progestatifs, In : Mauvais Jarvis P., Sitruk Ware R., éds. Médecine de la reproduction Gynécologie endocrinienne. Paris : Flammarion Médecine-Sciences, 553-586.
4. Bottiger L.E., Boman G., Eklund G., Westerhoim B 1980. Oral contraceptives and thromboembolic disease . effects of lowering estrogen content. Lancet: 1097-1 101.
5. Meade T.W., Greenberg G., Thompson S G 1980. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 mcg estrogen preparations. Br Med J 280 : 1157-1161.
6. Vessey M , Mant D., Smith A , Yeates D. 1986. Oral contraceptives and venous thromboembolism : findings in a large prospective study. Br Med J 292 : 526-529.
7. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. 1995. Venous thromboembolic disease and combined oral contraceptives : results of international multicentre case-control study. Lancet 346 : 1575-1582.
8. Croft P., Hannaford P.C. 1989. Risks factors For acute myocardial infarction in women : evidence from the Royal College of General Practitioners' Oral Contraception Study. Br Med J 298 : 165-168.
9. Lidegaard O. 1993. Oral contraception and risk of cerebral thromboembolic attack . results of a case-control study. Br Med J 306 : 956-963.
10. Hannaford P.C., Croft P.R., Kay C.R. 1994. Oral contraception and stroke. Evidence from the Royal College on General Practitioners' Oral Contraception Study. Stroke 25 : 935-942.
11. Meade T.W., Chakrabarti R , Haines A.P., Howarth D.J., North W.R.S., Stirling Y. 1977. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg estrogen. Lancet ii : 948-951.
12. Samsioe G. 1994. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obsf Gynecol 170: 1523-1527.
13. Jespersen J., Petersen K.R., Skouby S.O 1990. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 163 : 316-403.
14. Basdevant A., Conard J., Pelissier C. 1993. Haemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception 48 : 193-204.
15. Stampfer MJ., Willet W.C., Coiditz G.A, Speizer F.E., Hennekens C.H. 1988. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319 : 1313-1317.
16. Wahl P., Walden C, Knopp R., Hoover I., Wallece R., Heiss G., Rifkind B. 1983. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 308 : 862-867.
17. Godsland LF., et al. 1990. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323 : 1375-1381.
18. Godsland LF., Crook D. 1994. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol : 170: 1528-1536.
19. Basdevant A., Pelissier C., Conard J., Degrelle H., Guyene T.T., Thomas J. L. 1991. Effects of nomegestrol acetate (5 mg/d) on hormonal. metabolic and hemostatic parameters in premenopausal women Contraception 44 : 599-605
20. Godsland I.F , Wallon C., Felton C., Proudler A., Patel A., Wynn V. 1992. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74 : 64-70
21. Juhan-Vague I., Vague P., Alessi M.C., Badier C., Valadier J., Aillaud M.F., Atlan C. 1987. Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 133 : 331-336.
22. Castelli N.P. 1986. The triglyceride issue. A view from Framingham. Am Heart J 112 : 432-437.
23. Fruzetti F., Ricci C.N., Rioretti P. 1994 Haemostasis profile in smoking and non smoking women taking lowdose oral contraceptives. Contraception 46 : 579-592.
24. Sullivan J.M., Lobo R.A. 1993. Considerations for contraception in women with cardiovascular disorders. Am J Obstet Gynecol 168 : 2006-2011.
25. Lieberman E.H , et al. 1994. Estrogen improves endothelium dependent, flow mediated vasodilatation in post menopausal women. Ann Intern Med 121 : 936-941.
26. Adams M.R., Kaplan J.R., Manuck S.B. 1990. Inhibition of coronary artery atherosclerosis by 17-beta-estradiol in ovariectomized monkeys. Atherosclerosis 10 : 1051-1057.
27. Reis S.E., Gloth S.T., Blumenthal R.S., Resar J.R., Zacur H.A., Gerstenblith G., Brinker J.A. 1994. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in post menopausal women. Circulation 89 : 52-60.
28. Sack M.N., Rader DJ., Cannon III R.O. 1994. Estrogen and inhibition of oxidation of low-density lipoproteins in post menopausal women. Lancet 343 : 269-270.
29. Mikkola T., Turunen P., Avela K., Orpana A., Viinikka L., Ylikorkala O. 1995. β-estradiol stimulates prostacyclin but not endothelin production in human vascular endothelial cells, J Clin Endocrinol Metab 80: 1832-1836.
30. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. 1995. Effect of different progestogens in low estrogen oral contraceptives on venous thromboembolic disease Lancet 346: 1582-1588
31. Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., Mac R.A.E.K on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. 1996. Third generation oral contraceptives and risk of venous thromboembolic disorders : an international case-control study. Br Med J 312 : 83-88.
32. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Buller H.R., Vandenbroucke J.P. 1995. Enhancement by factor V Leiden mutation of risk deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 346 : 1593-1596.
33. Colditz G.A. for the Nurses' Health Study Research Group. 1994. Oral contraceptive use and mortality during the 12 years of follow-up : the Nurses' Health Study. Ann Intern Med 120 : 821-826.
34. Lewis M.A., Spitzer W.O., Heinemann L.A.J., Mac Rae K.D., Bruppacher R., Thorogood M. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. 1996. Third generation oral contraceptives and risk of myocardial infarction : an international case-control study. Br Med J 312 : 88-90.
35. Jick H., Jick S.S., Gurewich V., Wald Myers M., Vasilakis C. 1995. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 : 1589-1593.
36. Romieu I., Berlin J.A., Colditz G. 1990 Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 66 : 2253-2263.
37. Vessey M.P., McPherson K., Doll R. 1981. Breast cancer and oral contraceptives : findings in Oxford Family Planning Association Study. Br Med J 282 : 2093-2094.
38. Royal College of General Practitioners. 1981. Breast cancer and oral contraceptives : findings in Royal College of General Practitioners'study. Br Med J 282 : 2089-2093.
39. Trapido E.J. 1981. A prospective cohort study of oral contraceptives and breast cancer. J Natl Cancer Inst 67 : 1011-1015
40. Romcharans S., Pellegrin F.A., Ray R., Hsu J.P. 1981. The Walnut Creek Contraceptive Drug Study : a prospective study of the side effects of oral contraceptives (vol 3). An interim report : a comparison of disease occurence leading to hospitalization or death in users and nonusers of oral contraceptives. Washington : Washington DC US Government Printing Office (NIH publication no 81-564).
41. Romieu L, Willette W., Colditz G., Stampfer M., Rosner B., Speizer F. 1989. A prospective study of oral contraceptive use and the risk of breast cancer in women. J Natl Cancer Inst 81 : 1313-1321.
42. UK National Case Control Study Group. 1989. Oral contraceptive use and breast cancer in young women, Lancet i : 973-982.
43. Rookus M.A., Van Leeuwen S.E. 1994. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 344 : 844-851.
44. Centers for Disease Control, National Institute of Child Health and Human Development. 1987. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257 : 796-800.
45. The Cancer and Steroid Hormone Study Group. 1987. The reduction in risk of ovarian cancer associated with oral contraceptive use : the Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 316 . 650-655.
46. Gross T.P., Schlesselman J.J. 1994. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 83 : 419-424.
47. Schlesselman J.J. 1989. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 40 : 1-38.
48. Ursin G., Peters R.K , Henderson B.E., d'Ablaing III G., Monroe K R., Pike M.C. 1994. Oral contraceptive use and adenocarcinoma of cervix. Lancet 344 : 1390-1394.
49. Vessey M., Painter R. 1994. Oral contraceptive use and benign gallblader disease revisited. Contraception 50 : 167-173.
50. Grodstein F., Colditz G.A., Hunter DJ., Manson J.E., Willett W.C., Stampfer M.J. 1994. A prospective study of symptomatic gallstones in women : relation with oral contraceptives and other risk factors. Obstet Gynecol 84 : 207-214.
51. Rabe T., Feldmann K , Grunwald K., Runnebaum B. 1994. Liver tumours in women on oral contraceptives. Lancet 344 : 1568-1569.
52. Misheu D.R. 1982. Non contraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 142 : 809-816.
53. Polaneczky M., Slap G., Forke C., Rappaport A., Sondheimer S. 1994. The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. N Engl J Med 331 : 1201-1206.
54. Couzinet B., Young J., Chanson P., Brailly S., Thomas J.L., Schaison G. 1996. The androgen receptor does not mediate the antigonadotropic activity of the progestin nomegestrol acetate in women. J Clin Endocrinol Metab (sous presse).
55. Basdevant A., Conard J., Denis C., Guyenne T.T., Egloff M., Denys I. 1989. Effets métaboliques et hormonaux de l'administration de 1 mg/jour de promégestone (RU-5020) Gynecologie 40 : 17-23.
56. Pelissier C., Basdevant A., Conard J., Egloff M., Husson T , Guyenne T.T. 1987. Contraception progestative par l'acétate de chlormadinone chez des femmes à risque vasculaire : étude gynéco-endocrinienne, métabolique et vasculaire. Contracep Fertil Sexual 15 : 45-54.
57. Petersen K.R., Skouby S.O., Sidelmann J., Pedersen-Melsted L, Jespersen J. 1994. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 17 : 400-405.
58. Garg S.K., Chase H.P., Marshall G , Hoops S L., Holmes D.L, Jackson W.E. 1994. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271 : 1099-1102
59. Conard J. 1995. Résistance à la protéine C activée, médecine thérapeutique 8 828-833.
60. Vandenbroucke J.P., Rostert T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. 1994. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 34 : 1453-1457.
61. Silberstein S.D. 1992. The role of sex hormones in headache. Neurology 42 (suppl. 2) : 37-42.
62. Rothrock J., North J., Madden K., Lyden P., Fleck P., Dittrich H. 1993. Migraine and migrainous stroke : risk factors and prognosis. Neurology 43 : 2473-2476.
63. Jungers P., Dougados M., Pelissier C., Kuttenn F., Lesavre P., Bach J.F. 1982. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rhum 25 : 618-623.
64. Arden N.K , Lloyd M.E., Spector T.D., Hughes G.R.V. 1994. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 3 : 11-13
65. Couzinet B., Le Strat N., Ulmann A., Baulieu E.E., Schaison G. 1986. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). N Engl J Med 315 : 1565-1570.
66. Swahn M.L., Gemzell K., Bygdeman M. 1991 Contraception with mifepristone. Lancet 338 : 942-943.
67. Ledger W.L., Sweeting V.M., Hillier H., Baird D.R. 1992. Inhibition of ovulation by low dose mifepristone (RU-486). Human Reprod 7 : 945-950.
68. Hsueh A.J.W. 1995. Designer contraceptive pills. Human Reprod 8 : 1997-2000.